Hepatocellular carcinoma

Daniel F. Schafer; Michael F. Sorrell

doi:10.1016/S0140-6736(98)09148-X

Hepatocellular carcinoma

Daniel F. Schafer, Michael F. Sorrell

Research output: Contribution to journal › Review article › peer-review

526 Scopus citations

Abstract

Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.

Original language	English (US)
Pages (from-to)	1253-1257
Number of pages	5
Journal	Lancet
Volume	353
Issue number	9160
DOIs	https://doi.org/10.1016/S0140-6736(98)09148-X
State	Published - Apr 10 1999

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(98)09148-X

Cite this

@article{c7802269787f4397b2954976b2aaf485,

title = "Hepatocellular carcinoma",

abstract = "Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.",

author = "Schafer, {Daniel F.} and Sorrell, {Michael F.}",

year = "1999",

month = apr,

day = "10",

doi = "10.1016/S0140-6736(98)09148-X",

language = "English (US)",

volume = "353",

pages = "1253--1257",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "9160",

}

TY - JOUR

T1 - Hepatocellular carcinoma

AU - Schafer, Daniel F.

AU - Sorrell, Michael F.

PY - 1999/4/10

Y1 - 1999/4/10

N2 - Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.

AB - Hepatocellular carcinoma (HCC) for most patients is a terminal complication of chronic inflammatory and fibrotic liver disease. With regrettably few exceptions, treatment is largely palliative, and long-term survival is rare. However, the major causes of HCC worldwide are known and preventable. Hepatitis B and C exist only in man; the viruses have no known non-human reservoirs. Transmission of the viruses can be interrupted by vaccination against hepatitis B virus infection and improvements in medical techniques for hepatitis C, for which no vaccine has yet been developed.

UR - http://www.scopus.com/inward/record.url?scp=0033541491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033541491&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(98)09148-X

DO - 10.1016/S0140-6736(98)09148-X

M3 - Review article

C2 - 10217098

AN - SCOPUS:0033541491

SN - 0140-6736

VL - 353

SP - 1253

EP - 1257

JO - Lancet

JF - Lancet

IS - 9160

ER -

Hepatocellular carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this